Kadimastem Ltd.
Clinical Development of iTol-102, Allogenic Stem Cell Derived Islet Cells without Chronic Immunosuppression to cure Type 1 Diabetes — Israeli partner. US partner: iTolerance, Inc. (Miami (Florida)). Sector: Life Sciences, Pharma/Cell Therapy.